A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)
Status:
Recruiting
Trial end date:
2025-10-08
Target enrollment:
Participant gender:
Summary
RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab
in subjects with moderate to severe Rheumatoid Arthritis (RA)